Pilot randomised trial of a healthy eating behavioural intervention in uncontrolled asthma

Jun Ma1,2,3, Peg Strub4, Nan Lv1, Lan Xiao1, Carlos A. Camargo Jr5, A. Sonia Buist6, Philip W. Lavori7, Sandra R. Wilson1,2, Kari C. Nadeau8 and Lisa G. Rosas1,2

Affiliations: 1Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA. 2Dept of Medicine, Stanford University School of Medicine, Stanford, CA, USA. 3Dept of Health Policy and Administration, University of Illinois at Chicago School of Public Health, Chicago, IL, USA. 4Dept of Allergy, Asthma, and Immunology, The Permanente Medical Group, San Francisco Medical Center, San Francisco, CA, USA. 5Dept of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 6Pulmonary & Critical Care Medicine, Oregon Health & Science University, Portland, OR, USA. 7Dept of Health Research & Policy, Stanford University School of Medicine, Stanford, CA, USA. 8Dept of Paediatric Allergy and Immunology, Stanford University, Stanford, CA, USA.

Correspondence: Jun Ma, Dept of Health Policy and Administration, School of Public Health, University of Illinois at Chicago, Chicago, IL 60607, USA. E-mail: maj2015@uic.edu

ABSTRACT Rigorous research on the benefit of healthy eating patterns for asthma control is lacking.

We randomised 90 adults with objectively confirmed uncontrolled asthma and a low-quality diet (Dietary Approaches to Stop Hypertension (DASH) scores <6 out of 9) to a 6-month DASH behavioural intervention (n=46) or usual-care control (n=44). Intention-to-treat analyses used repeated-measures mixed models.

Participants were middle-aged, 67% female and multiethnic. Compared with controls, intervention participants improved on DASH scores (mean change (95% CI) 0.6 (0, 1.1) versus −0.3 (−0.8, 0.2); difference 0.9 (0.4, 1.5)) and the primary outcome, Asthma Control Questionnaire scores (−0.2 (−0.5, 0) versus 0 (−0.3, 0.3); difference −0.2 (−0.5, 0.1)) at 6 months. The mean group differences in changes in Mini Asthma Quality of Life Questionnaire overall and subdomain scores consistently favoured the intervention over the control group: overall 0.4 (95% CI 0, 0.8), symptoms 0.5 (0, 0.9), environment 0.4 (−0.1, 1.0), emotions 0.4 (−0.2, 0.9) and activities 0.3 (0, 0.7). These differences were modest, but potentially clinical significant.

The DASH behavioural intervention improved diet quality with promising clinical benefits for better asthma control and functional status among adults with uncontrolled asthma. A full-scale efficacy trial is warranted.

@ERSpublications
A dietary programme has clinical benefits for asthma control and functional status in adults with uncontrolled asthma http://ow.ly/R8zUn
Introduction
Asthma prevalence has increased in recent years, currently affecting >18 million US adults [1]. Diet composition changes and worsened diet quality have been implicated as contributing factors in this trend [2], as well as poor asthma control [3]. Some studies have investigated the potential benefit of certain foods (e.g., fruit, vegetables and fish) and nutrients (e.g., vitamins C, D and E, and ω-3 fatty acids) for improving asthma control in adults; however, the evidence is mixed and of insufficient quality to inform clinical and public health practice [4–7]. Several more recent studies focussed on dietary patterns rather than specific foods or nutrients and their association with asthma control in adults [6, 8]. A recent meta-analysis by Lv et al. [9] showed no association between dietary patterns and asthma prevalence or incidence in adults, although some individual studies included in the systematic review reported significant associations between dietary patterns and risk of uncontrolled asthma, measures of lung function such as forced expiratory volume in 1 s (FEV1) and/or frequency of asthma attacks. The review identified only one published randomised controlled trial (RCT) that examined two Mediterranean diet interventions compared with no-intervention control in 38 adults with symptomatic asthma. The trial showed the feasibility of improving Mediterranean diet scores, but no beneficial effect of either intervention on asthma control, lung function, asthma-related quality of life or inflammatory markers [8]. Additional RCTs are needed to examine the efficacy of healthy dietary patterns for asthma control.

In this RCT pilot study, “DASH for Asthma”, we sought to examine the potential efficacy of a behavioural intervention promoting Dietary Approaches to Stop Hypertension (DASH) to improve asthma control in adults with uncontrolled asthma and to determine whether a full-scale trial would be warranted according to a priori decision rules. The main study aims were to estimate the 95% confidence intervals of the net-of-control effects of the DASH behavioural intervention on the primary outcome, change in asthma control measured by the Juniper Asthma Control Questionnaire (ACQ) [10], and on secondary outcomes including specific manifestations of asthma indicative of current impairment (e.g., lung function, symptoms and rescue medication use) and future risk (e.g., asthma exacerbations). In addition, changes in DASH concordance index, adherence to the primary DASH daily goals, and changes in weight, blood pressure and lipids were assessed.

Methods
An Institutional Review Board of the Kaiser Foundation Research Institute in Northern California and the study Data and Safety Monitoring Board (DSMB) approved the study. All participants provided written informed consent. The trial protocol was published previously [11].

Study participants
Participants were recruited (February 15–December 12, 2013) from the Kaiser Permanente medical centres in San Francisco and Hayward. Inclusion criteria included age 18–70 years, body mass index (BMI) 18.5–39.9 kg·m−2, consuming a low-quality diet (defined as score <6 out of 9 total on the DASH concordance index summing nine nutrient targets, including total fat, saturated fat, protein, cholesterol, fibre, magnesium, calcium, sodium and potassium [12]) and confirmation of uncontrolled persistent asthma through a multistage screening process (i.e., electronic asthma registry queries, completion of the Asthma Control Test [13], pre- and post-bronchodilator spirometry, and if necessary, medical chart review by an asthma specialist) (online supplementary table E1). Exclusion criteria included serious medical or psychiatric conditions (e.g., chronic obstructive pulmonary disease, stroke, psychosis) or special life circumstances (e.g., pregnancy, planned relocation). Of the 2241 patients mailed recruitment letters after their primary care provider approved study contact, 805 patients declined participation, 757 were ineligible and 589 were not contactable or nonresponsive. This process yielded the target enrolment of 90 eligible and consenting participants (figure 1).

Randomisation and blinding
Participants were randomly assigned in a 1:1 ratio to receive the DASH intervention (n=46) or no intervention (n=44) while all participants continued usual care. Using a Web-based random allocation system [14], we applied Pocock’s minimisation, a covariate-adaptive randomisation method [15], to achieve better-than-chance between-treatment balance across six prognostic factors (age, sex, race/ethnicity, smoking status, DASH concordance index and the seven-item ACQ score). Efron’s biased-coin method [16] was employed to protect allocation concealment with use of non-extreme randomisation probabilities (i.e. 2/3 to 1/3). A designated study staff person who did not have the ability to influence the allocation system’s execution performed randomisation. The trial design precluded blinding participants or interventionists to treatment assignment; however, the investigators, DSMB members, outcome assessors and data analyst were masked throughout the trial.
Treatment arms

Intervention

Intervention participants received a dietician-delivered behavioural intervention that promoted the DASH eating pattern as recommended in the 2010 US Dietary Guidelines [17]. The intervention curriculum included an intensive phase (three individual and eight group sessions, 60 min each, over 3 months) and a maintenance phase (monthly or more frequent phone consultations depending on participant needs, preferences and availability). The intervention was grounded in social cognitive theory [18]. Interventionists used proven behaviour change strategies (e.g. self-monitoring, action planning and problem solving) to help participants achieve and maintain primary DASH daily goals adapted to their individual caloric needs for weight maintenance: 1) seven to 12 servings of fruit and vegetables, 2) two to four servings of low-fat/fat-free dairy products, 3) total fat grams at 27% of estimated caloric needs, and 4) ≤2300 mg of sodium. Exercise was not a component of the intervention. More intervention details are available in the protocol [11].

Control

Control participants received no intervention from the study. Regardless of group assignment, all participants continued to receive standard medical care from their providers, who were not informed of participants’ treatment assignment. Each participant watched a Kaiser Permanente standard asthma self-management educational video (10 min) as part of the baseline assessment visit.

FIGURE 1 CONSORT chart. ACQ: Asthma Control Questionnaire. #: ACQ score was computed as the mean of the complete seven-item scores (ACQ7) or the six-item scores (ACQ6) if forced expiratory volume in 1 s was missing because spirometry was not performed or not usable per American Thoracic Society standards.
Outcome measures

Of the 90 randomised participants, 83 (92%) were assessed at 3 and 6 months (figure 1). All outcome assessors were trained to perform the measurements and interviews per standardised protocols and procedures.

The ACQ [10] integrates seven components of asthma control, including five patient-reported asthma symptoms, reported need for bronchodilators and measured FEV1; all are scored on a seven-point scale (0–6), with a higher score indicating worse asthma control. The ACQ score was computed as the mean of the seven-item scores (ACQ7) or the six-item scores (ACQ6) if FEV1 was missing because spirometry was not performed or the test was invalid. Both measures have been validated [10, 19] and we used the same approach in another published asthma trial [20]. There were 90 participants with ACQ scores (88 ACQ7 and two ACQ6) at baseline, 79 (77 and two) at 3 months, and 82 (75 and seven) at 6 months.

Participants also completed the 15-item Mini Asthma-specific Quality of Life Questionnaire (MiniAQLQ) [21]. A change of at least 0.5 points is regarded as clinically significant for both the ACQ and MiniAQLQ [19]. Outcome assessors performed spirometry according to the American Thoracic Society (ATS) standards [22], with ongoing quality monitoring. Two independent respiratory therapists rated all spiromgrams. A valid test required a minimum of two manoeuvres meeting the ATS acceptability and reproducibility criteria, from among which the best parameter values were chosen for FEV1 and forced vital capacity (FVC) separately and used in data analyses. Outcome assessors also followed published protocols to obtain weight and blood pressure measurements [23, 24].

For dietary intake, outcome assessors conducted multiple-pass 24-h diet recalls [25], which is the current gold standard for diet assessment, with participants over the phone using the Windows-based Nutrition Data System for Research (Nutrition Coordinating Centre, University of Minnesota, Minneapolis, MN, USA). These data were used to compute participants’ DASH concordance index as a measure of overall diet quality [12]. Participants also completed fasting blood draws at the onsite clinical laboratory for assays of plasma glucose and lipid profile. Atopic status was determined by testing specific IgE antibodies to dust mite (Dermatophagoides pteronyssinus), animal dander (cat and dog), grasses (ragweed and timothy grass) and tree (juniper cedar) using ImmunoCAP Specific IgE (Phadia, Uppsala, Sweden).

Data abstracted from Kaiser Permanente of Northern California electronic health records included encounters with the healthcare system, diagnoses and pharmacy dispensing events during the 6 months before and after randomisation. Participants were interviewed at each follow-up visit about possible adverse events during the past 3 months and the study physician adjudicated the events per study safety protocol.

Statistical analyses

No participants were excluded after randomisation. Intention-to-treat analyses of between-treatment differences in primary and secondary outcomes tested for treatment-by-time interactions in repeated-measures mixed-effects linear (for continuous outcomes) or logistic models (for categorical outcomes). The fixed effects of each model consisted of the baseline value of the outcome of interest, randomisation balancing factors, treatment, time point and treatment-by-time interaction. The random effects accounted for repeated measures with a spatial power covariance structure which was selected based on the least Bayesian information criterion and for clustering of patients within primary care providers. Missing data were handled directly through maximum-likelihood estimation in mixed modelling. Least-square means (95% confidence intervals) were obtained from the models. All analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA).

As the primary goal of this pilot study was not hypothesis testing but estimation, we calculated the target sample size by controlling the length of the confidence interval, not by controlling the power of a statistical test at an appropriate alternative. We estimated that given a sample of 45 participants per arm with a projected 10% attrition at 6 months, the likelihood that the expected two-sided 95% confidence interval for an observed effect would have a standardised half-width no greater than 0.5 was 90% [26]. In other words, it was 90% or more likely that the estimated 95% confidence interval would not overlap the null if the observed effect was equivalent to a Cohen’s d=0.5 (medium effect) or larger. We specified a priori various scenarios of the observed effect and confidence interval, and the corresponding decisions about whether a full-scale trial would be warranted (see the protocol [11]).

Results

Baseline characteristics

Participants were middle-aged, mostly female and never-smokers; they were racially/ethnically and socioeconomically diverse (table 1). At baseline, they had low DASH scores (mean±SD) of 2.3±1.3 and poor asthma control (Asthma Control Test score 14.9±3.7; pre-bronchodilator FEV1/FVC 68.5±11.3%).

DOI: 10.1183/13993003.00591-2015
and ACQ averaged 1.3±0.8; 29% had asthma onset before 12 years of age by self-report and 74% were atopic according to a positive result (≥ 0.35 kU·L\(^{-1}\)) for any of the six allergen-specific IgEs tested.

### Overall diet quality and daily goal attainment

Mixed-model-based estimates showed that intervention participants had a significant net-of-control increase of 0.8 (95% CI 0.2, 1.5) in DASH score and 1.9 (0.8, 3.0) daily servings of fruit and vegetables at
6 months (table 2), which were also observed at 3 months (online supplementary table E2). Figure 2 shows the complete fitted distributions and sorted individual values of change in DASH scores. The Cohen’s d estimate based on unadjusted mean changes in DASH scores over 6 months of the two groups was 0.5, suggesting medium intervention effect (figure 3a). In addition, at 6 months intervention participants showed a net mean increase in low-fat/fat-free dairy servings, and net mean decreases in fat and sodium intake, although the 95% confidence intervals included the null. The percentage of intervention participants meeting the minimum daily DASH goals was 33% versus 8% of controls for seven servings of fruit and vegetables, 49% versus 53% for total fat grams at 27% of individualised caloric needs, 23% versus 15% for two servings of low-fat/fat-free dairy products, and 58% versus 40% for ≤2300 mg of sodium. Compared with the control group, the intervention group’s log-transformed odds ratios of reaching the minimum goal were greater for fruit and vegetable servings and sodium intake, although only the latter reached statistically significance (figure 4).

**Asthma control, asthma-specific functional status and lung function**

At 6 months, intervention participants had a net improvement of −0.2 (95% CI −0.5, 0.1) in ACQ score, and consistently favourable changes in MiniAQLQ overall and subdomain scores (figure 3a). The unadjusted Cohen’s d estimates ranged from 0.28 to 0.48 for these asthma outcomes, indicating small-to-medium intervention effects. Significantly higher percentages of intervention participants than controls achieved clinically important improvements of at least 0.5 in ACQ scores (28% versus 9%, p=0.04) and overall MiniAQLQ scores (55% versus 16%, p=0.004) (figure 3b). ACQ and MiniAQLQ results were unaffected by further adjustment for asthma long-term controller (i.e. beclomethasone canister equivalents, 1.5 mg of beclomethasone canister equivalents).

**TABLE 2 Estimated mean changes from baseline to 6 months in DASH score, asthma outcomes, weight and blood pressure in the intention-to-treat population**

<table>
<thead>
<tr>
<th>Intervention goal measure</th>
<th>Change from baseline to 6 months</th>
<th>Baseline</th>
<th>Intervention</th>
<th>Control</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DASH score</strong></td>
<td></td>
<td>2.3±1.3</td>
<td>0.6±0.3</td>
<td>−0.3±0.3</td>
<td>0.8 (0.2, 1.5)</td>
</tr>
<tr>
<td>Fruits and vegetables servings per day #</td>
<td></td>
<td>4.4±2.4</td>
<td>1.6±0.5</td>
<td>−0.3±0.5</td>
<td>1.9 (0.8, 3.0)</td>
</tr>
<tr>
<td>Fat g·day⁻¹</td>
<td></td>
<td>66.3±40.7</td>
<td>−5.3±4.8</td>
<td>−4.7±4.7</td>
<td>−0.5 [-11.6, 10.5]</td>
</tr>
<tr>
<td>Low fat/fat-free dairy servings per day #</td>
<td></td>
<td>1.0±0.9</td>
<td>0.2±0.2</td>
<td>−0.1±0.2</td>
<td>0.3 [-0.1, 0.7]</td>
</tr>
<tr>
<td>Sodium mg·day⁻¹</td>
<td></td>
<td>2718±1278</td>
<td>−117±197</td>
<td>−58±192</td>
<td>−58 [-529, 413]</td>
</tr>
<tr>
<td><strong>Asthma control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ACQ</td>
<td></td>
<td>1.3±0.8</td>
<td>−0.2±0.1</td>
<td>−0.0±0.1</td>
<td>−0.2 [-0.5, 0.1]</td>
</tr>
<tr>
<td><strong>Asthma-specific functional status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MiniAQLQ, overall</td>
<td></td>
<td>5.2±1.1</td>
<td>0.7±0.2</td>
<td>0.2±0.2</td>
<td>0.4 (0.0, 0.8)</td>
</tr>
<tr>
<td>MiniAQLQ, symptoms</td>
<td></td>
<td>5.2±1.3</td>
<td>0.6±0.2</td>
<td>0.1±0.2</td>
<td>0.5 (0.0, 0.9)</td>
</tr>
<tr>
<td>MiniAQLQ, environment</td>
<td></td>
<td>4.6±1.6</td>
<td>0.7±0.2</td>
<td>0.3±0.2</td>
<td>0.4 [-0.1, 1.0]</td>
</tr>
<tr>
<td>MiniAQLQ, emotions</td>
<td></td>
<td>4.9±1.5</td>
<td>0.7±0.2</td>
<td>0.3±0.2</td>
<td>0.4 [-0.2, 0.9]</td>
</tr>
<tr>
<td>MiniAQLQ, activities</td>
<td></td>
<td>6.0±1.0</td>
<td>0.6±0.2</td>
<td>0.2±0.2</td>
<td>0.3 [-0.0, 0.7]</td>
</tr>
<tr>
<td><strong>Spirometry lung function test</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV₁ L</td>
<td></td>
<td>2.6±0.8</td>
<td>−0.0±0.0</td>
<td>−0.0±0.0</td>
<td>0.0 [-0.1, 0.1]</td>
</tr>
<tr>
<td>FVC L</td>
<td></td>
<td>3.8±1.0</td>
<td>0.0±0.1</td>
<td>0.1±0.1</td>
<td>−0.0 [-0.2, 0.1]</td>
</tr>
<tr>
<td>FEV₁/FVC %</td>
<td></td>
<td>68.5±11.3</td>
<td>−0.4±1.1</td>
<td>−1.6±1.0</td>
<td>1.2 [-1.3, 3.7]</td>
</tr>
<tr>
<td><strong>Weight and blood pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Weight kg</td>
<td></td>
<td>76.5±15.9</td>
<td>−1.2±0.7</td>
<td>−1.1±0.7</td>
<td>−0.1 [-1.8, 1.5]</td>
</tr>
<tr>
<td>Body mass index kg·m⁻²</td>
<td></td>
<td>27.9±4.8</td>
<td>−0.5±0.2</td>
<td>−0.4±0.2</td>
<td>−0.1 [-0.7, 0.4]</td>
</tr>
<tr>
<td>Systolic blood pressure mmHg</td>
<td></td>
<td>117±14.4</td>
<td>−5.5±1.7</td>
<td>−3.6±1.6</td>
<td>−2.0 [-5.9, 2.0]</td>
</tr>
<tr>
<td>Diastolic blood pressure mmHg</td>
<td></td>
<td>74.9±8.9</td>
<td>−1.5±1.1</td>
<td>0.7±1.1</td>
<td>−2.2 [-4.7, 0.4]</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD (Baseline), covariate-adjusted, mixed-model-based means±SE (Intervention and Control), and covariate-adjusted, mixed-model-based mean (95% CI) (Difference). DASH: Dietary Approaches to Stop Hypertension (range 0–9 with higher scores indicating worse DASH concordance); ACQ: Asthma Control Questionnaire (range 0–6 with higher scores indicating worse asthma control); MiniAQLQ: Mini Asthma Quality of Life Questionnaire; FEV₁: forced expired volume in 1 s; FVC: forced vital capacity; #: servings were calculated using the Nutrition Data System for Research per the 2000 Dietary Guidelines for Americans (fruit: one serving=1 medium apple, banana, orange or pear, 0.5 cups of chopped, cooked or canned fruit, 0.25 cups dried fruit or 4 fl. oz of fruit juice; vegetables: one serving=1 cup of raw leafy vegetables, 0.5 cups of other cooked or raw vegetables or 4 fl. oz of vegetable juice; dairy: one serving=1 cup of milk or yogurt, 1.5 oz of natural cheese or 2 oz of processed cheese).
Spirometric parameters (FEV1, FVC and FEV1/FVC), weight and BMI were stable in both groups (table 2). Participants had normal mean blood pressure, fasting plasma glucose and fasting plasma lipids at baseline, with nonsignificant improvements in the intervention relative to the control group (table 2 and online supplementary table E3).

Asthma-related medications and healthcare encounters

Based on pharmacy dispensing records during the 6 months before randomisation, 21% of the 90 participants did not acquire any asthma controller medications, 72% acquired SABAs, 20% had asthma exacerbations requiring systemic corticosteroids, 1% had asthma-related hospitalisations and 11% had asthma-related emergency department visits. The corresponding numbers were 23%, 62%, 13%, 2% and 9%, respectively, during the 6 months after randomisation. The mean±SD beclomethasone canister equivalents of the total acquired long-term controller medications (excluding theophylline and maintenance systemic corticosteroids used for >15 days) were 8.3±8.9 and 7.9±9.0 in 6 months pre- and post-randomisation, respectively. The mean±SD albuterol canister equivalents of the total acquired SABAs were 1.9±2.2 and 1.7±1.9 over the same time periods. Intervention participants showed greater mean increases in long-term controller use and in outpatient visits, whereas they had greater mean decreases in SABA use and in asthma exacerbations requiring systemic corticosteroids; however, the confidence intervals were wide and all included the null (table 3).

Adverse events

Two hospitalisations occurred during the 6-month trial; neither was study-related and one was unexpected. This event involved a 41-year-old female intervention participant who presented to the emergency department with an asthma exacerbation, was treated with systemic corticosteroids and epinephrine, and then intubated and admitted to the intensive care unit for 2 days because of severe respiratory distress and acidosis. The patient was discharged with a corrected, stable respiratory status, and with prescription for a 5-day course of prednisone and azithromycin. The other hospitalisation occurred in a control participant with a history of persistent cough, acid reflux and abdominal pain who underwent laparoscopic hiatal hernia repair surgery. There were no deaths.
This was the first RCT of a behavioural intervention promoting the DASH eating pattern to examine the effects of a whole diet on asthma control. Compared with the control group, we found that the intervention led to significantly improved overall diet quality, and consistently favourable improvements in asthma control and related functional status as assessed by the ACQ and MiniAQLQ. A Cohen’s d of 0.28 for the DASH score.

**FIGURE 3** a) Baseline DASH, ACQ and MiniAQLQ scores, and their net-of-control improvements at 6 months. b) Percentage of participants meeting minimal clinically significant improvement (≥0.5) in ACQ and MiniAQLQ at 6 months. DASH: Dietary Approaches to Stop Hypertension; ACQ: Asthma Control Questionnaire; MiniAQLQ: Mini Asthma-specific Quality of Life Questionnaire. #: mean±SD; ¶: covariate-adjusted, mixed-model-based mean (95% CI); +: calculated as unadjusted between-group mean difference in change from baseline to 6 months divided by pooled standard deviation.

**Discussion**

This was the first RCT of a behavioural intervention promoting the DASH eating pattern to examine the effects of a whole diet on asthma control. Compared with the control group, we found that the intervention led to significantly improved overall diet quality, and consistently favourable improvements in asthma control and related functional status as assessed by the ACQ and MiniAQLQ. A Cohen’s d of 0.28 for the DASH score.
study protocol about the possible intervention effect [11]. Greater Cohen's d values were observed for improvements in overall and subdomain MiniAQLQ scores. The net-of-control mean improvement in the MiniAQLQ symptoms subdomain was 0.5 among intervention participants, which is considered clinically significant [19]. Furthermore, significantly higher percentages of intervention participants than controls achieved clinically significant improvements in ACQ and overall MiniAQLQ scores. Even though the confidence intervals for asthma medication use and asthma exacerbations (as well as cardiovascular risk factors) were wide, and almost all included the null, they changed consistently in favour of the intervention.

The available literature on the relationship between diet and asthma manifestations has focussed on individual nutrients and selected foods or food groups. A few intervention studies among adults with asthma investigated the relationship between individual nutrients and asthma manifestations using dietary supplements (e.g., vitamin C, vitamin E, fish oil/ω-3 fatty acid and selenium) or dietary modification (e.g., sodium reduction); however, the results have been largely disappointing [28–32]. Some epidemiologic studies have shown a protective effect of fruit, vegetable and fish intake on asthma manifestations in adults [5, 33, 34]. Other epidemiologic studies examined the relationship between dietary patterns and asthma outcomes, including asthma control, asthma-related quality of life, asthma symptoms and lung function [9]. Emerging data from mechanistic studies suggest oxidative stress and inflammatory response may explain the role of healthy eating in asthma symptomology and controls [35, 36].

In a two-stage RCT, Wood et al. [37] randomly assigned adults with objectively confirmed asthma to a high-antioxidant diet (five servings of vegetables and two servings of fruit daily; n=46) or a low-antioxidant diet (two or less servings of vegetables and one serving of fruit daily; n=91) for 14 days, at

Data are presented as means±sd or %, unless otherwise stated. ICS: inhaled corticosteroid; LABA: long-acting, inhaled β₂-agonist; LTRA: leukotriene modifier; SABA: short-acting β-agonist. a: extracted healthcare utilisation data from electronic health records included all visits by service type (emergency department, hospital inpatient or outpatient department) to Kaiser Permanente in Northern California and its contracted facilities, and pharmacy dispensing records; b: covariate-adjusted, mixed-model-based mean (95% CI) for between-treatment differences in change from 6 months before to 6 months after randomisation; c: estimated total number of canisters of beclomethasone to which an asthma controller medication dispensed for a patient in each 6-month period was equivalent in terms of its anti-inflammatory effectiveness (each dispensing of a controller medication [excluding theophylline and systemic corticosteroids used for >15 days], in any form or quantity, was assigned a weight representing its equivalent in fractional or multiple canisters of beclomethasone 80 mg [27]; weighted values were summed for each patient to obtain a cumulative measure of controller medication dose dispensed during the 6 months before and after randomisation separately); d: estimated total number of canisters of albuterol to which the amount of SABA dispensed in each 6-month period was equivalent in terms of its bronchodilator effectiveness (each dispensing of a controller medication, in any type or delivery mode, was assigned a weight representing its equivalent in canister of albuterol [27]; weighted values were summed for each patient to obtain a cumulative measure of dose dispensed during the 6 months before and after randomisation separately); e: defined as systemic corticosteroids (by tablet, suspension or injection) dispensed for 3–15 days of use; f: asthma-related healthcare encounters were visits with International Classification of Diseases, ninth revision (Clinical Modification) code 493 as a primary or secondary diagnosis.

### TABLE 3 Changes in asthma-related medication use and healthcare encounters

<table>
<thead>
<tr>
<th>Subjects n</th>
<th>All participants</th>
<th>Intervention</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months before randomisation</td>
<td>90</td>
<td>46</td>
<td>44</td>
</tr>
<tr>
<td>6 months after randomisation</td>
<td>90</td>
<td>46</td>
<td>44</td>
</tr>
<tr>
<td>Use of long-term controllers</td>
<td>79</td>
<td>74</td>
<td>84</td>
</tr>
<tr>
<td>Type of long-term controllers</td>
<td>77</td>
<td>80</td>
<td>73</td>
</tr>
</tbody>
</table>

Data are presented as means±sd or %, unless otherwise stated. ICS: inhaled corticosteroid; LABA: long-acting, inhaled β₂-agonist; LTRA: leukotriene modifier; SABA: short-acting β-agonist. a: extracted healthcare utilisation data from electronic health records included all visits by service type (emergency department, hospital inpatient or outpatient department) to Kaiser Permanente in Northern California and its contracted facilities, and pharmacy dispensing records; b: covariate-adjusted, mixed-model-based mean (95% CI) for between-treatment differences in change from 6 months before to 6 months after randomisation; c: estimated total number of canisters of beclomethasone to which an asthma controller medication dispensed for a patient in each 6-month period was equivalent in terms of its anti-inflammatory effectiveness (each dispensing of a controller medication [excluding theophylline and systemic corticosteroids used for >15 days], in any form or quantity, was assigned a weight representing its equivalent in fractional or multiple canisters of beclomethasone 80 mg [27]; weighted values were summed for each patient to obtain a cumulative measure of controller medication dose dispensed during the 6 months before and after randomisation separately); d: estimated total number of canisters of albuterol to which the amount of SABA dispensed in each 6-month period was equivalent in terms of its bronchodilator effectiveness (each dispensing of a controller medication, in any type or delivery mode, was assigned a weight representing its equivalent in canister of albuterol [27]; weighted values were summed for each patient to obtain a cumulative measure of dose dispensed during the 6 months before and after randomisation separately); e: defined as systemic corticosteroids (by tablet, suspension or injection) dispensed for 3–15 days of use; f: asthma-related healthcare encounters were visits with International Classification of Diseases, ninth revision (Clinical Modification) code 493 as a primary or secondary diagnosis.

ACQ change qualifies as a probably positive finding according to the various scenarios pre-specified in the study protocol about the possible intervention effect [11]. Greater Cohen's d values were observed for improvements in overall and subdomain MiniAQLQ scores. The net-of-control mean improvement in the MiniAQLQ symptoms subdomain was 0.5 among intervention participants, which is considered clinically significant [19]. Furthermore, significantly higher percentages of intervention participants than controls achieved clinically significant improvements in ACQ and overall MiniAQLQ scores. Even though the confidence intervals for asthma medication use and asthma exacerbations (as well as cardiovascular risk factors) were wide, and almost all included the null, they changed consistently in favour of the intervention.

The available literature on the relationship between diet and asthma manifestations has focussed on individual nutrients and selected foods or food groups. A few intervention studies among adults with asthma investigated the relationship between individual nutrients and asthma manifestations using dietary supplements (e.g., vitamin C, vitamin E, fish oil/ω-3 fatty acid and selenium) or dietary modification (e.g., sodium reduction); however, the results have been largely disappointing [28–32]. Some epidemiologic studies have shown a protective effect of fruit, vegetable and fish intake on asthma manifestations in adults [5, 33, 34]. Other epidemiologic studies examined the relationship between dietary patterns and asthma outcomes, including asthma control, asthma-related quality of life, asthma symptoms and lung function [9]. Emerging data from mechanistic studies suggest oxidative stress and inflammatory response may explain the role of healthy eating in asthma symptomology and controls [35, 36].

In a two-stage RCT, Wood et al. [37] randomly assigned adults with objectively confirmed asthma to a high-antioxidant diet (five servings of vegetables and two servings of fruit daily; n=46) or a low-antioxidant diet (two or less servings of vegetables and one serving of fruit daily; n=91) for 14 days, at
which point remaining participants of the latter group were further randomised to receive placebo (n=33) or tomato extract (45 mg lycopene daily; n=31) and all those in the high-antioxidant diet group (n=40) received placebo [37]. The intervention continued until week 14 or until an exacerbation occurred; 79 (58%) of the initial 137 participants attended final visits. The authors concluded that a high-antioxidant diet led to improved FEV1 and FVC, and a lower risk of asthma exacerbation, compared with a low-antioxidant diet, associated with evidence of reduced systemic inflammation, but that the antioxidant supplement had no effect on inflammation or clinical outcomes compared with placebo. Despite its shortcomings (e.g. short duration, high attrition and unclear level of blinding), the trial provided the first direct evidence that a whole-food approach rich in fruit and vegetables could be more important than isolated antioxidant supplementation in the management of asthma. As noted earlier, another small (n=38) and short duration (12 weeks) RCT concluded that promoting a Mediterranean diet was feasible, and worth examining for its clinical benefit, in adults with symptomatic asthma [8].

The current study contributes importantly to this very limited dietary pattern-asthma RCT literature by being the first RCT of a DASH-promoting behavioural intervention. The methodological limitations (e.g. small sample size, short intervention and follow-up duration) are reflective of a pilot study. Importantly, the intervention under study significantly improved DASH scores, an index of overall diet quality, mostly attributable to increased fruit and vegetable intake and reduced sodium intake over the 6-month period. The magnitudes of improvement in DASH scores [38] and in individual daily dietary goal achievements (e.g. fruit, vegetables and dairy) [39, 40] are comparable with similar dietary interventions in different populations and settings. Study participants reported an average of 4.4 servings of fruit and vegetables at baseline, which may be higher than usual intake of the general US adult population, possibly due to greater access to fruit and vegetables in California [41, 42]. Generally, US adults who have lower fruit and vegetable intake may have a higher likelihood of observing an improvement in overall diet quality with the intervention. This pilot trial showed, for the first time, that a DASH-promoting behavioural intervention significantly improved diet quality with promising clinical benefits for better asthma control and functional status among adults with uncontrolled asthma. The intervention proved to be safe, with no evidence of increased adverse effects on asthma medication use, exacerbations or acute healthcare utilisation (hospitalisations and emergency visits). These results provide good evidence that full-scale RCTs to more definitively examine the efficacy of this intervention and any modifications that may enhance its effectiveness are warranted.

Acknowledgements

We are indebted to the following individuals for their instrumental contributions to the conduct of the study: Veronica Luna, Andrea Blonstein, Elizabeth Jameiro and Nancy Wittels (Palo Alto Medical Foundation Research Institute, Palo Alto, CA, USA); Ranna Modir, Jennifer Waldrop and Jodi Thirtyacre (Kaiser Permanente of Northern California, San Francisco, CA, USA). We wish to thank the DASH Data and Safety Monitoring Board members, William Haskell, Ware G. Kuschner and Manisha Desai (Stanford University, Stanford, CA, USA), and extend special thanks to the DASH participants and their families who made this study possible. We also would like to acknowledge Unni C. Nygaard (Stanford University, Stanford, CA, USA) for her comments on the manuscript. The study was conducted while J. Ma was a faculty member at the Palo Alto Medical Foundation Research Institute.

References

Mickleborough TD, Lindley MR, Ray S. Dietary salt, airway inflammation, and diffusion capacity in ASTHMA | J. MA ET AL.


